Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
Gastrointestinal Stromal Tumor
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Childhood Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 5, 2024. Captured 2026-09-09.
Cancer in children and adolescents is rare, although the overall incidence has slowly increased since 1975.[1] Children and adolescents with cancer should be referred to medical centers that have a multidisciplinary team of cancer specialists with experience treating the cancers that occur during childhood and adolescence. This multidisciplinary team approach incorporates the skills of the following pediatric specialists and others to ensure that children receive treatment, supportive care, and rehabilitation to achieve optimal survival and quality of life:
Sources: 1
Primary care physicians.
Pediatric surgeons.
Pathologists.
Pediatric radiation oncologists.
Pediatric medical oncologists and hematologists.
Ophthalmologists.
Rehabilitation specialists.
Pediatric oncology nurses.
Social workers.
Child-life professionals.
Psychologists.
Nutritionists.
For specific information about supportive care for children and adolescents with cancer, see the summaries on Supportive and Palliative Care.
Sources: Supportive and Palliative Care
The American Academy of Pediatrics has outlined guidelines for pediatric cancer centers and their role in the treatment of children and adolescents with cancer.[2] At these centers, clinical trials are available for most types of cancer that occur in children and adolescents, and the opportunity to participate is offered to most patients and their families. Clinical trials for children and adolescents diagnosed with cancer are generally designed to compare potentially better therapy with current standard therapy. Other types of clinical trials test novel therapies when there is no standard therapy for a cancer diagnosis. Most of the progress in identifying curative therapies for childhood cancers has been achieved through clinical trials. Information about ongoing clinical trials is available from the NCI website.
Sources: 2 · NCI website
Dramatic improvements in survival have been achieved for children and adolescents with cancer. Between 1975 and 2020, childhood cancer mortality decreased by more than 50%.[3-5] Childhood and adolescent cancer survivors require close monitoring because side effects of cancer therapy may persist or develop months or years after treatment. For information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors, see Late Effects of Treatment for Childhood Cancer.
Sources: 3 · 5 · Late Effects of Treatment for Childhood Cancer
Childhood cancer is a rare disease, with about 15,000 cases diagnosed annually in the United States in individuals younger than 20 years.[6] The U.S. Rare Diseases Act of 2002 defines a rare disease as one that affects populations smaller than 200,000 people in the United States. Therefore, all pediatric cancers are considered rare.
Sources: 6 · Rare Diseases Act of 2002
The designation of a rare tumor is not uniform among pediatric and adult groups. In adults, rare cancers are defined as those with an annual incidence of fewer than six cases per 100,000 people. They account for up to 24% of all cancers diagnosed in the European Union and about 20% of all cancers diagnosed in the United States.[7,8] In children and adolescents, the designation of a rare tumor is not uniform among international groups, as follows:
A consensus effort between the European Union Joint Action on Rare Cancers and the European Cooperative Study Group for Rare Pediatric Cancers estimated that 11% of all cancers in patients younger than 20 years could be categorized as very rare. This consensus group defined very rare cancers as those with annual incidences of fewer than two cases per 1 million people. However, three additional histologies (thyroid carcinoma, melanoma, and testicular cancer) with incidences of more than two cases per 1 million people were also included in the very rare group due to a lack of knowledge and expertise in the management of these tumors.[9]
Sources: 9
The Children's Oncology Group defines rare pediatric cancers as those listed in the International Classification of Childhood Cancer subgroup XI, which includes thyroid cancers, melanomas and nonmelanoma skin cancers, and multiple types of carcinomas (e.g., adrenocortical carcinomas, nasopharyngeal carcinomas, and most adult-type carcinomas such as breast cancers and colorectal cancers).[10] These diagnoses account for about 5% of the cancers diagnosed in children aged 0 to 14 years and about 27% of the cancers diagnosed in adolescents aged 15 to 19 years.[4] Most cancers in subgroup XI are either melanomas or thyroid cancers, with other cancer types accounting for only 2% of the cancers diagnosed in children aged 0 to 14 years and 9.3% of the cancers diagnosed in adolescents aged 15 to 19 years.
These rare cancers are extremely challenging to study because of the relatively few patients with any individual diagnosis, the predominance of rare cancers in the adolescent population, and the small number of clinical trials for adolescents with rare cancers.
Information about these tumors may also be found in sources relevant to adults with cancer, such as Gastrointestinal Stromal Tumors Treatment.
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Childhood Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 5, 2024. Captured 2026-09-09.
Treatment options for pediatric gastrointestinal stromal tumors (GIST) include the following:
Observation.
Surgery.
Targeted therapy.
Once the diagnosis of pediatric GIST is established, patients should be referred to medical centers with expertise in the treatment of GIST.[1,2]
Given the indolent course of the disease in pediatric patients, it is reasonable to avoid extensive initial surgeries and to withhold subsequent resections unless needed to address symptoms such as obstruction or bleeding.[3,4]
Tumor samples are evaluated for variants in KIT (exons 9, 11, 13, 17), PDGFRA (exons 12, 14, 18), and BRAF (V600E).[1,2] Treatment options for GIST depend on whether a variant is detected.
GIST with a KIT or PDGFRA variant: Pediatric patients who harbor KIT or PDGFRA variants are managed like adults. For more information, see Gastrointestinal Stromal Tumors Treatment.
Succinate dehydrogenase (SDH)-deficient GIST: Approximately one-half of all patients with wild-type GIST are SDH deficient.[5] For most pediatric patients with SDH-deficient GIST, surgical resection of localized disease is recommended because of its indolent course. Extensive surgery and repeated surgical resections should be avoided.
Sources: 5
This approach is supported by a study of 76 patients with wild-type GIST who underwent surgery for newly diagnosed and recurrent disease.[5]
Sources: 5
Only 9% of patients experienced a fatal event, whereas 71% (54 patients) developed tumor recurrence or progression at a median of 2.5 years.
For this population, the 1-year event-free survival (EFS) rate was 73%, the 5-year EFS rate was 24%, and the 10-year EFS rate was 16%.
Factors associated with an increased risk of recurrence included metastatic disease and elevated mitotic rate. SDH status and extent of surgical resection did not influence the risk of recurrence.
Among 33 patients who underwent reoperation for recurrent disease, each subsequent resection was associated with a lower EFS rate.
In patients with SDH-deficient GIST, responses to imatinib, regorafenib, vandetanib, sunitinib, and guadecitabine are uncommon.[3,6-9]
In a review of ten patients who were treated with imatinib mesylate, one patient experienced a partial response and three patients had stable disease.[3]
Sources: 3
In the phase III SWOG Cancer Research Network intergroup S0033 (NCT00009906) trial, 20 tumors from patients presumed to have wild-type disease were resequenced.[8]
Sources: S0033 (NCT00009906) · 8
In the phase III SWOG Cancer Research Network intergroup S0033 (NCT00009906) trial, 20 tumors from patients presumed to have wild-type disease were resequenced.[8]
Twelve of these tumors were identified as having SDH variants, and only one patient (8.3%) experienced a partial response to imatinib.[10]
Sources: 10
In another study, sunitinib appeared to show more activity.[11]
Sources: 11
In another study, sunitinib appeared to show more activity.[11]
In six children with imatinib-resistant GIST, one patient had a partial response, and five patients had stable disease.
The combination of olaparib and temozolomide produced symptomatic relief and response in one pediatric patient with multiply relapsed SDH-deficient GIST who had osseous and mediastinal disease.[12]
Sources: 12
In a phase II trial of guadecitabine, no partial or complete responses were seen in seven patients (aged 18–57 years) with recurrent or refractory SDH-deficient GIST.[13]
Sources: 13
Unlike recommendations for adults, the use of adjuvant imatinib cannot be recommended in children with SDH-deficient GIST.[14]
Sources: 14
Source: Childhood Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 5, 2024. Captured 2026-09-09.
Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Sources: NCI website · ClinicalTrials.gov website
Source: Childhood Gastrointestinal Stromal Tumors (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
There are different types of treatment for children and adolescents with GIST. You and your child's care team will work together to decide treatment. Many factors will be considered, such as your child's overall health, whether the tumor has changes to the KIT, PDGFRA, or SDH genes, and whether the cancer is newly diagnosed or has come back.
Your child's treatment plan will include information about the cancer, the goals of treatment, treatment options, and the possible side effects. It will be helpful to talk with your child's care team before treatment begins about what to expect. For help every step of the way, visit our booklet, Children with Cancer: A Guide for Parents.
Types of treatment your child might have include:
Children with a GIST that has changes in the KIT or PDGFRA gene are treated with targeted therapy. Targeted therapy uses drugs or other substances to block the action of specific enzymes, proteins, or other molecules involved in the growth and spread of cancer cells. Imatinib and sunitinib are targeted therapies approved for adults with GIST and may be used in children and adolescents. Learn more about Targeted Therapy to Treat Cancer.
Sources: molecules · Imatinib · sunitinib · Targeted Therapy to Treat Cancer
Children with a GIST that is SDH-deficient are treated with surgery to remove the tumor. More surgery may be needed if an intestinal blockage or bleeding occurs.
If the cancer comes back after treatment, your child's doctor will talk with you about what to expect and possible next steps. There might be treatment options that may shrink the cancer or control its growth. If there are no treatments, your child can receive care to control symptoms from cancer so they can be as comfortable as possible.
Source: Childhood Gastrointestinal Stromal Tumors (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Cancer treatments can cause side effects. Which side effects your child might have depends on the type of treatment they receive, the dose, and how their body reacts. Talk with your child's treatment team about which side effects to look for and ways to manage them.
To learn more about side effects that begin during treatment for cancer, visit Side Effects.
Sources: side effects · Side Effects
Problems from cancer that begin 6 months or later after treatment and continue for months or years are called late effects. Late effects of cancer treatment may include:
physical problems
changes in mood, feelings, thinking, learning, or memory
second cancers (new types of cancer) or other conditions
Some late effects may be treated or controlled. It is important to talk with your child's doctors about the possible late effects caused by some treatments. Learn more about Late Effects of Treatment for Childhood Cancer.
Gastrointestinal Stromal Tumor
ClinicalTrials.gov recordGastrointestinal Stromal Tumors in children and adolescents